Z Gastroenterol 2013; 51(11): 1329-1330
DOI: 10.1055/s-0033-1350545
Kommentiertes Referat
© Georg Thieme Verlag KG Stuttgart · New York

Nab-Paclitaxel als neue Therapieoption des Pankreaskarzinoms

Nab-Paclitaxel as new Therapeutic Option for Pancreatic Cancer
P. Michl
Further Information

Publication History

Publication Date:
15 November 2013 (online)

Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA. Nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer. Cancer Discovery 2012; 2: 260 – 269.

Von Hoff DD, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Moore MJ, Seay TE, Tjulandin S, Ma WW, Saleh MN, Harris M, Reni M, Ramanathan RK, Tabernero J, Hidalgo M, Van Cutsem E, Goldstein D, Wei X, Iglesias JL, Renschler MF. Results of a Randomized Phase III Trial (MPACT) of Weekly Nab-Paclitaxel plus Gemcitabine Versus Gemcitabine Alone for Patients with Metastatic Adenocarcinoma of the Pancreas with PET and CA19 – 9 Correlates. J Clin Oncol 2013; 31 (suppl; abstract 4005).